Intercepting multiple myeloma before it fully develops has long been a tantalizing but elusive goal. For the roughly 10–15% of smoldering myeloma patients whose disease is classified as high-risk — facing a median progression timeline of under two years — finding a treatment that genuinely alters that trajectory could redefine how oncology approaches pre-malignant plasma cell disease.
The ImmunoPRISM trial, a randomized phase 2 study published in Nature Medicine, tested teclistamab — a BCMA×CD3 bispecific T-cell engager — against the established standard of lenalidomide plus dexamethasone in patients with high-risk smoldering multiple myeloma. Teclistamab redirects a patient's own cytotoxic T cells to destroy BCMA-expressing malignant plasma cells, a mechanism already validated in relapsed/refractory active myeloma. In the ImmunoPRISM cohort, patients receiving teclistamab achieved meaningfully higher rates of complete clinical response compared with those on lenalidomide-dexamethasone, suggesting the immunological firepower of bispecific engagement may be better suited to clearing pre-symptomatic disease burden than conventional immunomodulatory therapy.
Several important caveats temper enthusiasm. This is a phase 2 trial, meaning it was powered for response signals rather than definitive clinical endpoints like progression-free survival or overall survival. The critical question — whether deeper responses translate into durable prevention of conversion to active myeloma — remains unanswered, as the investigators themselves acknowledge that longer follow-up is essential. Additionally, teclistamab carries a known toxicity profile including cytokine release syndrome and infections, risks that take on heightened ethical weight when treating patients who may never have progressed regardless of intervention. In the broader landscape, this builds on the CESAR and GEM-CESAR trials that established deep response as achievable in high-risk smoldering disease, but pushes the therapeutic class firmly toward immunotherapy. If durable progression prevention is confirmed at longer follow-up, this could represent a genuine paradigm shift toward curative-intent interception in pre-malignant myeloma.